Sunday, June 14, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Beijing 2022: China readies for Winter Olympics as pressure grows

For the first time since the original coronavirus outbreak closed China’s borders, the country is preparing to allow foreigners to enter again in large numbers for the winter Olympics next February.

This had not seemed like it would pose much of a problem. People had become accustomed to life without many Covid restrictions, with authorities stamping out each outbreak of the virus as it came along.

But everything changed when the highly-contagious Delta variant made its way into China via an airport in the eastern city of Nanjing.

In July and August it quickly spread to dozens of cities and towns, threatening China’s status of having the virus controlled.

As they had before, authorities pursued a goal of full elimination.

The strategy is always the same. Phone app health clearance is implemented in order to enter public buildings, track and trace methods go into overdrive and, as infected people are identified, their housing estates placed into lockdown.

Source: BBC

https://www.bbc.com/news/world-asia-china-58196467

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!